To develop innovative treatments we need the expertise of healthcare professionals.

I need the optimal treatment for my disease. Together with pharma companies, I conduct clinical trials with new drugs. This is how I contribute to improving patient care.

Clinical trials pathway

- **Phase 1:** Initial safety testing
  - 20-100 healthy volunteers

- **Phase 2:** Assessment of safety and efficacy
  - 100-500 patient volunteers

- **Phase 3:** Demonstration of safety and efficacy
  - 1000+ patient volunteers

**Bayer Pharma AG**
13342 Berlin, Germany
www.bayer.com

**Transparency on Transfers of Value to Physicians**

Learn more bayer.com/tov-hcp

Date: 09.02.2016
Disclosure of Payments to Healthcare Professionals

Pharmaceutical industry and healthcare professionals collaborate in a range of activities in preclinical research, clinical development as well as clinical practice and patient outcome. We at Bayer are convinced that making this collaboration more transparent, helps to contribute towards a better understanding of the importance and value of this relationship for medical care.

As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and in line with our company values we fully endorse the EFPIA Disclosure Code. In accordance with this code we disclose payments as well as benefits in kind to healthcare professionals and healthcare organizations.

Collaborative Research

Benefits Patients and Society

The close cooperation with healthcare professionals and their continuous education is key to achieving better outcomes for the patients we strive to help.

Implementing the EFPIA Disclosure Code

Under the EFPIA Disclosure Code, all EFPIA member companies, including Bayer, publish all direct and indirect, monetary and non-monetary transfers of value related to the development and commercialization of prescription-only human pharmaceuticals.

Level of Compensation

Healthcare professionals are compensated for their expertise and the services they provide in this context to the pharmaceutical industry. The level of payments and transfers of value depend on the kind of activity, level of expertise, and amount of time.

Individual or Aggregated Disclosure?

Transfers of value to healthcare professionals will be reported on an individual or an aggregated basis. Should a healthcare professional not grant his/her consent for individual disclosure, then transfers of value will be reported on an aggregated basis. Transfers of value in the area of ‘Research and Development’ will always be reported on an aggregated level, as regulated by the EFPIA Disclosure Code.

Full Disclosure

We believe that only complete disclosure provides a fair picture of our relationship to a healthcare professional, and therefore will not disclose any partial data at the individual level.

Data Privacy

Bayer fully respects the importance of data privacy and data security. Therefore, we take multiple steps to protect data in compliance with data protection policies required and audited by local and global authorities. High data security mechanisms are in place to ensure data are protected against external attacks and manipulation.

Development of new drugs takes more than 10 years. Doctors, scientists and thousands of patients work together until a new treatment is available for patients.

40 Leading European Companies in 33 Countries are Committed to the EFPIA Disclosure Code

The EFPIA Disclosure Code is a code of conduct that requires all EFPIA member companies to disclose transfers of value to healthcare professionals and healthcare organizations.

Level of Compensation

Healthcare professionals are compensated for their expertise and the services they provide in this context to the pharmaceutical industry. The level of payments and transfers of value depend on the kind of activity, level of expertise, and amount of time.
To develop innovative treatments we need the expertise of healthcare professionals.

Together with pharma companies, I conduct clinical trials with new drugs. This is how I contribute to improving patient care.

Clinical trials pathway

Phase 1: Initial safety testing
20 - 100 healthy volunteers

Phase 2: Assessment of safety and efficacy
100 - 500 patient volunteers

Phase 3: Demonstration of safety and efficacy
1000+ patient volunteers

Transparency on Transfers of Value to Physicians

Science For A Better Life
Bayer Pharma AG
13342 Berlin, Germany
www.bayer.com
Disclosure of Payments to Healthcare Professionals

Pharmaceutical industry and healthcare professionals collaborate in a range of activities in preclinical research, clinical development as well as clinical practice and patient outcome. We at Bayer are convinced that making this collaboration more transparent, helps to contribute towards a better understanding of the importance and value of this relationship for medical care.

As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and in line with our company values we fully endorse the EFPIA Disclosure Code. In accordance with this code we disclose payments as well as benefits in kind to healthcare professionals and healthcare organizations.

Collaborative Research
Benefits Patients and Society

The close cooperation with healthcare professionals and their continuous education is key to achieving better outcomes for the patients we strive to help.

Implementing the EFPIA Disclosure Code

Under the EFPIA Disclosure Code, all EFPIA member companies, including Bayer, publish all direct and indirect, monetary and non-monetary transfers of value related to the development and commercialization of prescription-only human pharmaceuticals.

40 Leading European Companies in 33 Countries are Committed to the EFPIA Disclosure Code

The EFPIA Disclosure Code is a code of conduct that requires all EFPIA member companies to disclose transfers of value to healthcare professionals and healthcare organizations.

Level of Compensation

Healthcare professionals are compensated for their expertise and the services they provide in this context to the pharmaceutical industry. The level of payments and transfers of value depend on the kind of activity, level of expertise, and amount of time.

Individual or Aggregated Disclosure?

Transfers of value to healthcare professionals will be reported on an individual or an aggregated basis. Should a healthcare professional not grant his/her consent for individual disclosure, then transfers of value will be reported on an aggregated level. Transfers of value in the area of ‘Research and Development’ will always be reported on an aggregated level, as regulated by the EFPIA Disclosure Code.

Data Privacy

Bayer fully respects the importance of data privacy and data security. Therefore, we take multiple steps to protect data in compliance with the data protection policies required and audited by local and global authorities. High data security mechanisms are in place to ensure data are protected against external attacks and manipulation.

Full Disclosure

We believe that only complete disclosure provides a fair view of our relationship to a healthcare professional, and therefore do not disclose any partial data at the individual level.

Development of new drugs takes more than 10 years. Doctors, scientists and thousands of patients work together until a new treatment is available for patients.

Implementation of the EFPIA Disclosure Code

Under the EFPIA Disclosure Code, all EFPIA member companies, including Bayer, publish all direct and indirect, monetary and non-monetary transfers of value related to the development and commercialization of prescription-only human pharmaceuticals.

Level of Compensation

Healthcare professionals are compensated for their expertise and the services they provide in this context to the pharmaceutical industry. The level of payments and transfers of value depend on the kind of activity, level of expertise, and amount of time.

Individual or Aggregated Disclosure?

Transfers of value to healthcare professionals will be reported on an individual or an aggregated basis. Should a healthcare professional not grant his/her consent for individual disclosure, then transfers of value will be reported on an aggregated level. Transfers of value in the area of ‘Research and Development’ will always be reported on an aggregated level, as regulated by the EFPIA Disclosure Code.

Data Privacy

Bayer fully respects the importance of data privacy and data security. Therefore, we take multiple steps to protect data in compliance with the data protection policies required and audited by local and global authorities. High data security mechanisms are in place to ensure data are protected against external attacks and manipulation.

Full Disclosure

We believe that only complete disclosure provides a fair view of our relationship to a healthcare professional, and therefore do not disclose any partial data at the individual level.

Development of new drugs takes more than 10 years. Doctors, scientists and thousands of patients work together until a new treatment is available for patients.
Disclosure of Payments to Healthcare Professionals

Pharmaceutical industry and healthcare professionals collaborate in a range of activities in preclinical research, clinical development as well as clinical practice and patient outcome. We at Bayer are convinced that making this collaboration more transparent helps to contribute towards a better understanding of the importance and value of this relationship for medical care.

As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and in line with our company values we fully endorse the EFPIA Disclosure Code. In accordance with this code we disclose payments as well as benefits in kind to healthcare professionals and healthcare organizations.

Implementing the EFPIA Disclosure Code

Under the EFPIA Disclosure Code, all EFPIA member companies, including Bayer, publish all direct and indirect, monetary and non-monetary transfers of value to healthcare professionals and healthcare organizations.

Level of Compensation

Healthcare professionals are compensated for their expertise and the services they provide in this context to the pharmaceutical industry. The level of payments and transfers of value depend on the kind of activity, level of expertise, and amount of time.

Individual or Aggregated Disclosure?

Transfers of value to healthcare professionals will be reported on an individual or an aggregated basis. Should a healthcare professional not grant his/her consent for individual disclosure, then transfers of value will be reported on an aggregated basis. Transfers of value in the area of ‘Research and Development’ will always be reported on an aggregated level, as regulated by the EFPIA Disclosure Code.

Full Disclosure

We believe that only complete disclosure provides a fair view of our relationship to a healthcare professional, and therefore do not disclose any partial data at the individual level.

Data Privacy

Bayer fully respects the importance of data privacy and data security. Therefore we take multiple steps to protect data in compliance with data privacy policies required and audited by local and global authorities. High data security mechanisms are in place to ensure data are protected against external attacks and manipulation.

40 Leading European Companies in 33 Countries are Committed to the EFPIA Disclosure Code

The EFPIA Disclosure Code is a code of conduct that requires all EFPIA member companies to disclose transfers of value to healthcare professionals and healthcare organizations.

Level of Compensation

Healthcare professionals are compensated for their expertise and the services they provide in this context to the pharmaceutical industry. The level of payments and transfers of value depend on the kind of activity, level of expertise, and amount of time.

Individual or Aggregated Disclosure?

Transfers of value to healthcare professionals will be reported on an individual or an aggregated basis. Should a healthcare professional not grant his/her consent for individual disclosure, then transfers of value will be reported on an aggregated basis. Transfers of value in the area of ‘Research and Development’ will always be reported on an aggregated level, as regulated by the EFPIA Disclosure Code.

Full Disclosure

We believe that only complete disclosure provides a fair view of our relationship to a healthcare professional, and therefore do not disclose any partial data at the individual level.

Data Privacy

Bayer fully respects the importance of data privacy and data security. Therefore we take multiple steps to protect data in compliance with data privacy policies required and audited by local and global authorities. High data security mechanisms are in place to ensure data are protected against external attacks and manipulation.

Under the EFPIA Disclosure Code, all EFPIA member companies, including Bayer, publish all direct and indirect, monetary and non-monetary transfers of value related to the development and commercialization of prescription-only human pharmaceuticals.
To develop innovative treatments we need the expertise of healthcare professionals. I need the optimal treatment for my disease. Together with pharma companies, I conduct clinical trials with new drugs. This is how I contribute to improving patient care.

Clinical trials pathway:

Phase 1: Initial safety testing
- 20 - 100 healthy volunteers

Phase 2: Assessment of safety and efficacy
- 100 - 500 patient volunteers

Phase 3: Demonstration of safety and efficacy
- 1000+ patient volunteers

Transparency on Transfers of Value to Physicians

Learn more at bayer.com/tov-hcp

Bayer Pharma AG
13342 Berlin, Germany
www.bayer.com